Opthea Valuation

Is OPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OPT (A$0.38) is trading below our estimate of fair value (A$5.05)

Significantly Below Fair Value: OPT is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for OPT?

Other financial metrics that can be useful for relative valuation.

OPT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue761.4x
Enterprise Value/EBITDA-1.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does OPT's PB Ratio compare to its peers?

The above table shows the PB ratio for OPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average47.7x
PYC PYC Therapeutics
20.3x-17.1%AU$606.6m
IMU Imugene
2.2x50.7%AU$433.6m
DXB Dimerix
152.2xn/aAU$269.6m
RAC Race Oncology
16.2x-14.1%AU$330.4m
OPT Opthea
n/a54.0%AU$403.8m

Price-To-Book vs Peers: OPT has negative equity and a Price-To-Book Ratio (-6x) compared to the peer average (47.7x).


Price to Earnings Ratio vs Industry

How does OPT's PE Ratio compare vs other companies in the AU Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.2%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.2%
n/an/an/a
No more companies

Price-To-Book vs Industry: OPT has negative equity and a Price-To-Book Ratio (-6x) compared to the Australian Biotechs industry average (3.4x).


Price to Book Ratio vs Fair Ratio

What is OPT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OPT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OPT's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OPT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.38
AU$0.87
+128.8%
64.9%AU$1.63AU$0.28n/a3
Jul ’25AU$0.34
AU$0.87
+152.0%
64.9%AU$1.63AU$0.28n/a3
Jun ’25AU$0.51
AU$0.88
+72.0%
63.4%AU$1.63AU$0.30n/a3
May ’25AU$0.62
AU$0.90
+44.7%
65.0%AU$1.69AU$0.30n/a3
Apr ’25AU$0.74
AU$0.79
+6.4%
82.9%AU$1.71AU$0.30n/a3
Mar ’25AU$0.67
AU$0.84
+26.0%
86.8%AU$1.88AU$0.30n/a3
Feb ’25AU$0.48
AU$0.84
+75.8%
86.8%AU$1.88AU$0.30n/a3
Jan ’25AU$0.57
AU$1.15
+101.0%
71.7%AU$2.05AU$0.30n/a4
Dec ’24AU$0.49
AU$1.15
+133.8%
71.7%AU$2.05AU$0.30n/a4
Nov ’24AU$0.33
AU$1.15
+247.1%
71.7%AU$2.05AU$0.30n/a4
Oct ’24AU$0.33
AU$1.29
+291.8%
77.6%AU$2.64AU$0.30n/a4
Sep ’24AU$0.44
AU$1.10
+149.4%
99.4%AU$2.64AU$0.30n/a3
Aug ’24AU$0.59
AU$1.65
+177.4%
53.6%AU$2.80AU$0.65n/a3
Jul ’24AU$0.55
AU$1.65
+200.1%
53.6%AU$2.80AU$0.65AU$0.343
Jun ’24AU$0.60
AU$1.65
+175.0%
53.6%AU$2.80AU$0.65AU$0.513
May ’24AU$0.71
AU$1.65
+130.8%
53.6%AU$2.80AU$0.65AU$0.623
Apr ’24AU$0.73
AU$1.65
+126.1%
53.6%AU$2.80AU$0.65AU$0.743
Mar ’24AU$0.84
AU$1.65
+96.5%
53.6%AU$2.80AU$0.65AU$0.673
Feb ’24AU$0.95
AU$1.70
+79.0%
48.7%AU$2.80AU$0.80AU$0.483
Jan ’24AU$0.92
AU$1.70
+85.8%
48.7%AU$2.80AU$0.80AU$0.573
Dec ’23AU$0.94
AU$1.70
+79.9%
48.7%AU$2.80AU$0.80AU$0.493
Nov ’23AU$1.00
AU$1.70
+70.0%
48.7%AU$2.80AU$0.80AU$0.333
Oct ’23AU$1.17
AU$1.70
+45.3%
48.7%AU$2.80AU$0.80AU$0.333
Sep ’23AU$1.13
AU$1.80
+60.0%
55.6%AU$2.80AU$0.80AU$0.442
Aug ’23AU$1.31
AU$1.70
+29.8%
52.9%AU$2.60AU$0.80AU$0.592
Jul ’23AU$1.20
AU$1.70
+42.3%
52.9%AU$2.60AU$0.80AU$0.552

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.